Senseonics (NYSE:SENS) Trading 6.2% Higher – Here’s Why

Senseonics Holdings, Inc. (NYSE:SENS) shares traded up 6.2% during mid-day trading on Monday . The company traded as high as $0.90 and last traded at $0.90. 1,711,615 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 14,655,776 shares. The stock had previously closed at $0.85.

Analyst Upgrades and Downgrades

SENS has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $2.00 target price on shares of Senseonics in a report on Friday, November 15th. StockNews.com started coverage on shares of Senseonics in a report on Thursday, December 26th. They issued a “sell” rating on the stock.

Senseonics Trading Up 2.4 %

The business has a fifty day moving average price of $0.84 and a 200-day moving average price of $0.53. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The company has a market cap of $517.93 million, a P/E ratio of -6.69 and a beta of 0.69.

Senseonics (NYSE:SENS) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.09). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. On average, analysts forecast that Senseonics Holdings, Inc. will post -0.14 earnings per share for the current year.

Insider Buying and Selling at Senseonics

In other news, CFO Frederick T. Sullivan purchased 124,933 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $0.38 per share, with a total value of $47,474.54. Following the acquisition, the chief financial officer now owns 2,478,844 shares in the company, valued at approximately $941,960.72. The trade was a 5.31 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Timothy T. Goodnow acquired 315,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were purchased at an average price of $0.31 per share, with a total value of $97,650.00. Following the completion of the transaction, the chief executive officer now owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Institutional Trading of Senseonics

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC raised its stake in Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after acquiring an additional 167,970 shares in the last quarter. Geode Capital Management LLC lifted its stake in Senseonics by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after purchasing an additional 179,103 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Senseonics during the third quarter worth $117,000. Ridgecrest Wealth Partners LLC acquired a new stake in shares of Senseonics during the 4th quarter valued at $60,000. Finally, Renaissance Technologies LLC bought a new stake in Senseonics during the 4th quarter worth $720,000. 12.36% of the stock is currently owned by institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.